Annaliesa S Anderson
Overview
Explore the profile of Annaliesa S Anderson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
4218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith W, Seger W, Chawana R, Jefferies Z, de Monerri N, Feng Y, et al.
J Infect Dis
. 2025 Mar;
PMID: 40036340
Background: Maternal group B streptococcus (GBS) infection is associated with substantial risk of preterm birth and infant mortality. Preventative approaches to protect infants from GBS infection are needed. Methods: In...
2.
Tuttle J, Allais C, Allerton C, Anderson A, Arcari J, Aschenbrenner L, et al.
J Med Chem
. 2025 Feb;
PMID: 40019854
In early 2020, severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infections leading to COVID-19 disease reached a global level leading to the World Health Organization (WHO) declaration of a...
3.
Neutel J, Erdem R, Jiang Q, Cannon K, Stacey H, Newton R, et al.
Vaccines (Basel)
. 2025 Feb;
13(2).
PMID: 40006705
Concomitant administration may improve vaccination rates. This analysis of a phase 1/2 randomized study included 1073 healthy ≥65-year-olds who previously received ≥3 mRNA COVID-19 vaccine doses. Participants received concomitantly administered...
4.
Diya O, Gayed J, Lowry F, Ma H, Bangad V, Mensa F, et al.
Vaccine
. 2025 Feb;
52:126869.
PMID: 39999538
Background: COVID-19 remains a substantial burden in vulnerable populations, including older adults and immunocompromised individuals. It was recommended that 2024-2025 COVID-19 vaccine formulations should target a monovalent JN.1 lineage. Here...
5.
Martinon-Torres F, Lamberth E, Martinez S, Salamanca de la Cueva I, Zolotas L, Oladipupo I, et al.
Hum Vaccin Immunother
. 2025 Feb;
21(1):2463194.
PMID: 39993937
Invasive meningococcal disease is an uncommon but serious disease predominantly affecting children. This phase 2b study evaluated MenABCWY in 6-month-old infants followed by MenB-fHbp and MenABCWY in 2-month-old infants, the...
6.
de Monerri N, Che Y, Lees J, Jasti J, Wu H, Griffor M, et al.
PLoS Pathog
. 2025 Feb;
21(2):e1012325.
PMID: 39970181
Adhesion of E. coli to the urinary tract epithelium is a critical step in establishing urinary tract infections. FimH is an adhesin positioned on the fimbrial tip which binds to...
7.
Koski S, Martinon-Torres F, Ramet M, Zolotas L, Newton R, Maansson R, et al.
Infect Dis Ther
. 2025 Jan;
14(2):463-481.
PMID: 39883399
Introduction: Infants and young children typically have the highest age-related risk of invasive meningococcal disease. The immunogenicity and safety of a single primary dose and a booster of a meningococcal...
8.
Simoes E, Pahud B, Madhi S, Kampmann B, Shittu E, Radley D, et al.
Obstet Gynecol
. 2025 Jan;
145(2):157-167.
PMID: 39746212
Objective: To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination...
9.
Madhi S, Kampmann B, Simoes E, Zachariah P, Pahud B, Radley D, et al.
Obstet Gynecol
. 2025 Jan;
145(2):147-156.
PMID: 39746206
Objective: To describe preterm birth frequency and newborn and infant outcomes overall and among preterm children in the MATISSE (Maternal Immunization Study for Safety and Efficacy) trial of maternal vaccination...
10.
Modjarrad K, Che Y, Wu H, Cadima C, Muik A, Maddur M, et al.
NPJ Vaccines
. 2024 Nov;
9(1):229.
PMID: 39567521
As SARS-CoV-2 evolves, increasing in potential for greater transmissibility and immune escape, updated vaccines are needed to boost adaptive immunity to protect against COVID-19 caused by circulating strains. Here, we...